Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Hungary’s largest pharma company Gedeon Richter and Ireland-headquartered generics major Actavis have announced positive results from a Phase III trial of cariprazine to prevent relapse in schizophrenia patients. 20 January 2015
Swiss pharma company Addex Therapeutics is to enter into a collaboration with the Dystonia Medical Research Foundation to explore the use of dipraglurant to treat dystonia. 19 January 2015
US drugmaker Supernus Pharmaceuticals says it has sued privately-held generics firm Par Pharmaceutical for infringement of four patents covering its antiepileptic drug Trokendi XR (topiramate). 19 January 2015
Neuropore Therapies, a wholly-owned US subsidiary of Austria’s Ever Neuro Pharma, has entered into a worldwide collaboration and agreement with Belgium’s largest drugmaker, UCB. 18 January 2015
Australian biotech firm Novogen has announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells. 16 January 2015
US specialty drugmaker Depomed has entered into a definitive agreement to acquire the US rights to the Nucynta (tapentadol) franchise from Johnson & Johnson subsidiary Janssen Pharmaceuticals, for $1.05 billion. 16 January 2015
Netherlands-based biotech firm Treeway has entered into a collaboration with Dutch gene therapy company uniQure to develop a gene therapy treatment for ALS. 15 January 2015
German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia who have come together to test innovative treatments for the prevention of Alzheimer’s dementia. 15 January 2015
Japanese pharma company Sumitomo Dainippon and its US subsidiary Sunovion Pharmaceuticals have jointly filed patent infringement law suits against Emcure Pharmaceuticals and InvaGen Pharmaceuticals. 15 January 2015
The US Food and Drug Administration has approved US drugmaker AbbVie’s Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson’s disease. 13 January 2015
US biotech major Biogen Idec has agreed to acquire independent UK-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company, in a deal that is expected to close during the first quarter of this year. 12 January 2015
Switzerland’s biopharma company AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer’s disease and potentially other tauopathies. 12 January 2015
Swiss drugmaker Mundipharma Laboratories and its independent associated company, Purdue Pharmaceuticals, have entered into a global multi-program discovery and development collaboration with privately held Spanish firm Laboratorios Esteve. 12 January 2015
US biotech firm Egalet Corp has in-licensing two innovative approved pain products transforming Egalet into a fully integrated specialty pharmaceutical company focused on developing and commercializing products indicated to treat patients living with moderate to severe pain. 9 January 2015
Italy-based Newron Pharmaceuticals and its partner Zambon have received a recommendation from the Euroean Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) that the European Commission approve Xadago (safinamide). 7 January 2015
Shares of Ireland-headquartered biotech firm Alkermes closed up 2.6% to $60.93, having risen as much as 5% yesterday, after the company has released positive top-line results from the FORWARD-1 study. 7 January 2015
Ireland-headquartered generics major Actavis has had its motion to expedite its appeal of a lower court ruling requiring it to continue distribution of Namenda (memantine HCl) immediate-release tablets approved. 7 January 2015
23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche, have joined forces to generate whole genome sequencing data for around 3,000 people in 23andMe's Parkinson's disease community. 6 January 2015
The humble aspirin, originally used only as a pain killer but since has been identified as a factor in the fight against heart attacks and strokes, could also have an important role in the prevention of dementia. 5 January 2015